Research recommendation(s) from an individual piece of guidance
|Guidance:||Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib|
|Date issued:||November 2010|
Research recommendations coming out of this guidance
- The use of plasma level measurement to individualise imatinib treatment and to optimise long-term outcomes.
- A national register should be maintained for all people with gastrointestinal stromal tumours (GISTs) being treated with imatinib, sunitinib and best supportive care
- The use of mutational analysis to predict individual response to imatinib treatment and long-term outcomes.
This page was last updated: 20 March 2014